This was followed by the approval of programmed cell death protein-1 (PD-1) inhibitors, nivolumab (Opdivo) and pembrolizumab (Keytruda), in 2014 for the treatment of unresectable or metastatic melanoma. This evidence concerns the gene PDCD1 and metastatic melanoma.